References in periodicals archive ?
* Vilazodone (Viibryd), which may have fewer sexual side effects than some of the other antidepressants.
He previously served in commercial leadership roles in the biotech industry, including at Intrexon Corporation as vice president, Marketing and Communications, and as vice president of Marketing at Clinical Data Inc., where he was responsible for the US commercial launch of the company's flagship product, Viibryd, a novel antidepressant.
The National Pregnancy Registry for Antidepressants (844-405-6185) is studying amitriptyline (Elavil), amoxapine (Asendin), bupropion (Forfivo XL and Wellbutrin), Citalopram (Celexa), clomipramine (Anafranil), desipramine (Norpramin), desvenlafaxine (Prisiq), doxepin (Sinequan), escitalopram (Lexapro), fluvoxamine (Luvox), fluoxetine (Prozac), imipramine (Tofranil), isocarboxazid (Marplan), levomilnacipran (Fetzima), maprotiline (Ludiomil), mirtazapine (Remeron), nefazodone (Serzone), nortriptyline (Pamelor), paroxetine (Paxil), phenelzine (Nardill), protriptyline (Vivactil), selegiline (Emsam), sertraline (Zoloft), tranylcypromine (Parnate), trazodone (Desyrel), trimipramine (Surmontil), venlafaxine (Effexor), and vilazodone (Viibryd).
Actavis will add the Alzheimer's disease treatment Namenda and newer drugs like the antidepressant Viibryd to its product portfolio with the latest in a string of multibillion-dollar acquisitions that have swelled the drugmaker's size in recent years.
Namenda sales rose 7.8% to $396.3mn in the second quarter while those of the company's depression drug, Viibryd, were up about 19% at $47.4mn.
In 2011, vilazodone (Viibryd), another antidepressant with possibly fewer sexual side effects, received FDA approval.
These findings led to the 2011 Food and Drug Administration approval of vilazodone hydrochloride under the trade name of Viibryd for treatment of major depressive disorder (MDD) in adults.
In June, Forest Labs launched Vilazodone (Viibryd), a drug that is thought to work via two mechanisms of action, one of them novel.
Forest Laboratories, via its unit Magnolia Acquisition Corp, is also offering a contingent consideration of up to USD6 per unit depending on the achievement of certain milestones related to the Viibryd product.
"'Unlike other antidepressants, Viibryd [vilazodone hydrochloride] is the first and only drug that is both a potent selective serotonin reuptake inhibitor and serotonin 1A [5-[HT.sub.1A]] receptor partial agonist in one single molecule," said Clinical Data's CEO Drew Fromkin during a call with analysts and investors on Jan.